Nexpovio is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is used together with two other medicines, bortezomib and dexamethasone, in adults who have received at least one previous treatment. It is also used together with dexamethasone in adults who have received at least four previous treatments and whose disease has worsened since the last treatment. Nexpovio contains the active substance selinexor.
Therapeutic Indication
### Therapeutic indication NEXPOVIO is indicated - in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. - in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Therapeutic Area (MeSH)
ATC Code
L01XX66
ATC Item
selinexor
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Selinexor | N/A | 塞利尼索 |
EMA Name
Nexpovio
Medicine Name
Nexpovio
Aliases
N/ANo risk management plan link.
